Compare CYTK & CAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | CAVA |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.7B |
| IPO Year | 2004 | 2023 |
| Metric | CYTK | CAVA |
|---|---|---|
| Price | $63.34 | $60.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 20 |
| Target Price | ★ $84.81 | $80.00 |
| AVG Volume (30 Days) | 1.8M | ★ 3.6M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 151.16 |
| EPS | N/A | ★ 1.16 |
| Revenue | $87,211,000.00 | ★ $1,132,074,000.00 |
| Revenue This Year | $341.94 | $24.00 |
| Revenue Next Year | $75.44 | $20.75 |
| P/E Ratio | ★ N/A | $52.28 |
| Revenue Growth | ★ 2609.26 | 23.93 |
| 52 Week Low | $29.31 | $43.41 |
| 52 Week High | $70.98 | $144.49 |
| Indicator | CYTK | CAVA |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 41.92 |
| Support Level | $62.13 | $60.82 |
| Resistance Level | $65.88 | $65.35 |
| Average True Range (ATR) | 2.59 | 2.76 |
| MACD | 0.07 | -1.38 |
| Stochastic Oscillator | 54.84 | 0.69 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.